PAA
LKFT

Peregrine Asset Advisers’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Peregrine Asset Advisers’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,000
Closed -$395K – 104
2020
Q2 		$395K Hold
2,000
– – 0.22% 64
2020
Q1 		$392K Buy
+2,000
New +$430K 0.3% 54

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

Peregrine Asset Advisers's LKFT Position: Q3 2020 in Review

Peregrine Asset Advisers sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2020, closing a stake of 2,000 shares — an estimated $395K sold.

Peregrine Asset Advisers first reported a position in LKFT in Q1 2020 and held it in 2 quarters. The position peaked at $395K in Q2 2020. 119 funds tracked by Wall St. Rank hold LKFT as of Q3 2020.

  • Peregrine Asset Advisers reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2020 after selling out during the quarter.
  • Peregrine Asset Advisers sold 2,000 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2020, an estimated $395K.
  • Peregrine Asset Advisers first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2020 and held it in 2 quarters.
  • Peregrine Asset Advisers's Lakefront Biotherapeutics American Depositary Shares position peaked at $395K in Q2 2020.
  • 119 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2020.

Based on Peregrine Asset Advisers's 13F filing for Q3 2020, filed 13 Nov 2020.